Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity

被引:89
作者
Nadal, Xavier [1 ]
del Rio, Carmen [2 ]
Casano, Salvatore [1 ]
Palomares, Belen [2 ]
Ferreiro-Vera, Carlos [1 ]
Navarrete, Carmen [3 ]
Sanchez-Carnerero, Carolina [1 ]
Cantarero, Irene [2 ]
Bellido, Maria Luz [3 ]
Meyer, Stefan [1 ]
Morello, Gaetano [4 ]
Appendino, Giovanni [5 ]
Munoz, Eduardo [2 ]
机构
[1] Phytoplant Res SL, Cordoba, Spain
[2] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba, Hosp Univ Reina Sofia, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain
[3] Vivacell Biotechnol SL, Cordoba, Spain
[4] Emerald Hlth Pharmaceut, San Diego, CA USA
[5] Univ Piemonte Orientale, Dipartimento Sci Farmaco, Novara, Italy
关键词
ACTIVATED-RECEPTOR-GAMMA; HUNTINGTONS-DISEASE; MITOCHONDRIAL DYSFUNCTION; CONCISE GUIDE; LIGAND; ROSIGLITAZONE; CANNABINOIDS; PHARMACOLOGY; AFFINITY; DEGRADATION;
D O I
10.1111/bph.14019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND PURPOSE Phytocannabinoids are produced in Cannabis sativa L. in acidic form and are decarboxylated upon heating, processing and storage. While the biological effects of decarboxylated cannabinoids such as Delta(9)-tetrahydrocannabinol have been extensively investigated, the bioactivity of Delta(9)-tetahydrocannabinol acid (Delta(9)-THCA) is largely unknown, despite its occurrence in different Cannabis preparations. Here we have assessed possible neuroprotective actions of Delta(9)-THCA through modulation of PPAR gamma pathways. EXPERIMENTAL APPROACH The effects of six phytocannabinoids on PPAR gamma binding and transcriptional activity were investigated. The effect of Delta(9)-THCA on mitochondrial biogenesis and PPAR gamma coactivator 1-alpha expression was investigated in Neuro-2a (N2a) cells. The neuroprotective effect was analysed in STHdh(Q111/Q111) cells expressing a mutated form of the huntingtin protein and in N2a cells infected with an adenovirus carrying human huntingtin containing 94 polyQ repeats (mHtt-q94). The in vivo neuroprotective activity of Delta(9)-THCA was investigated in mice intoxicated with the mitochondrial toxin 3-nitropropionic acid (3-NPA). KEY RESULTS Cannabinoid acids bind and activate PPAR gamma with higher potency than their decarboxylated products. Delta(9)-THCA increased mitochondrial mass in neuroblastoma N2a cells and prevented cytotoxicity induced by serum deprivation in STHdh(Q111/Q111) cells and by mutHtt-q94 in N2a cells. Delta(9)-THCA, through a PPAR gamma-dependent pathway, was neuroprotective in mice treated with 3-NPA, improving motor deficits and preventing striatal degeneration. In addition, Delta(9)-THCA attenuated microgliosis, astrogliosis and up-regulation of proinflammatory markers induced by 3-NPA. CONCLUSIONS AND IMPLICATIONS Delta(9)-THCA shows potent neuroprotective activity, which is worth considering for the treatment of Huntington's disease and possibly other neurodegenerative and neuroinflammatory diseases.
引用
收藏
页码:4263 / 4276
页数:14
相关论文
共 56 条
  • [1] Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders
    Agarwal, Swati
    Yadav, Anuradha
    Chaturvedi, Rajnish Kumar
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 483 (04) : 1166 - 1177
  • [2] Cannabinoid ester constituents from high-potency Cannabis sativa
    Ahmed, Safwat A.
    Ross, Samir A.
    Slade, Desmond
    Radwan, Mohamed M.
    Zulfiqar, Fazila
    ElSohly, Mahmoud A.
    [J]. JOURNAL OF NATURAL PRODUCTS, 2008, 71 (04): : 536 - 542
  • [3] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors
    Alexander, Stephen P. H.
    Davenport, Anthony P.
    Kelly, Eamonn
    Marrion, Neil
    Peters, John A.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Southan, Christopher
    Davies, Jamie A.
    Aldrich, R.
    Attali, B.
    Back, M.
    Barnes, N. M.
    Bathgate, R.
    Beart, P. M.
    Becirovic, E.
    Biel, M.
    Birdsall, N. J.
    Boison, D.
    Brauner-Osborne, H.
    Broeer, S.
    Bryant, C.
    Burnstock, G.
    Burris, T.
    Cain, D.
    Calo, G.
    Chan, S. L.
    Chandy, K. G.
    Chiang, N.
    Christakos, S.
    Christopoulos, A.
    Chun, J. J.
    Chung, J. -J.
    Clapham, D. E.
    Connor, M. A.
    Coons, L.
    Cox, H. M.
    Dautzenberg, F. M.
    Dent, G.
    Douglas, S. D.
    Dubocovich, M. L.
    Edwards, D. P.
    Farndale, R.
    Fong, T. M.
    Forrest, D.
    Fowler, C. J.
    Fuller, P.
    Gainetdinov, R. R.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) : 5744 - 5869
  • [4] THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Nuclear hormone receptors
    Alexander, Stephen P. H.
    Cidlowski, John A.
    Kelly, Eamonn
    Marrion, Neil
    Peters, John A.
    Benson, Helen E.
    Faccenda, Elena
    Pawson, Adam J.
    Sharman, Joanna L.
    Southan, Christopher
    Davies, Jamie A.
    Aldrich, R.
    Attali, B.
    Back, M.
    Barnes, N. M.
    Bathgate, R.
    Beart, P. M.
    Becirovic, E.
    Biel, M.
    Birdsall, N. J.
    Boison, D.
    Brauner-Osborne, H.
    Broeer, S.
    Bryant, C.
    Burnstock, G.
    Burris, T.
    Cain, D.
    Calo, G.
    Chan, S. L.
    Chandy, K. G.
    Chiang, N.
    Christakos, S.
    Christopoulos, A.
    Chun, J. J.
    Chung, J. -J.
    Clapham, D. E.
    Connor, M. A.
    Coons, L.
    Cox, H. M.
    Dautzenberg, F. M.
    Dent, G.
    Douglas, S. D.
    Dubocovich, M. L.
    Edwards, D. P.
    Farndale, R.
    Fong, T. M.
    Forrest, D.
    Fowler, C. J.
    Fuller, P.
    Gainetdinov, R. R.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) : 5956 - 5978
  • [5] Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor γ
    Ambrosio, Andre L. B.
    Dias, Sandra M. G.
    Polikarpov, Igor
    Zurier, Robert B.
    Burstein, Sumner H.
    Garratt, Richard C.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (25) : 18625 - 18633
  • [6] Basavargiappa BS, 2017, J NEUROCHEM, V160, P480
  • [7] Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease
    Blazquez, Cristina
    Chiarlone, Anna
    Sagredo, Onintza
    Aguado, Tania
    Ruth Pazos, M.
    Resel, Eva
    Palazuelos, Javier
    Julien, Boris
    Salazar, Maria
    Boerner, Christine
    Benito, Cristina
    Carrasco, Carolina
    Diez-Zaera, Maria
    Paoletti, Paola
    Diaz-Hernandez, Miguel
    Ruiz, Carolina
    Sendtner, Michael
    Lucas, Jose J.
    de Yebenes, Justo G.
    Marsicano, Giovanni
    Monory, Krisztina
    Lutz, Beat
    Romero, Julian
    Alberch, Jordi
    Gines, Silvia
    Kraus, Juergen
    Fernandez-Ruiz, Javier
    Galve-Roperh, Ismael
    Guzman, Manuel
    [J]. BRAIN, 2011, 134 : 119 - 136
  • [8] Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: A speculative explanation
    Borlongan, CV
    Nishino, H
    Sanberg, PR
    [J]. NEUROSCIENCE RESEARCH, 1997, 28 (03) : 185 - 189
  • [9] The energetics of Huntington's disease
    Browne, SE
    Beal, MF
    [J]. NEUROCHEMICAL RESEARCH, 2004, 29 (03) : 531 - 546
  • [10] IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding
    Cer, R. Z.
    Mudunuri, U.
    Stephens, R.
    Lebeda, F. J.
    [J]. NUCLEIC ACIDS RESEARCH, 2009, 37 : W441 - W445